AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: ligand

newssourceFORcompanyinformationcontent1releasesmarket

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

PRESS RELEASE

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Biosensors Market worth $54.37 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 8, 2025 /PRNewswire/ -- The global biosensors market is projected to grow from USD 34.51 billion in 2025 to USD 54.37...

Biosensors Market worth $54.37 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 8, 2025 /PRNewswire/ -- The global biosensors market is projected to grow from USD 34.51 billion in 2025 to USD 54.37...

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLigand

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers